BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

380 related articles for article (PubMed ID: 7578806)

  • 1. 3D-QSAR of human immunodeficiency virus (I) protease inhibitors. III. Interpretation of CoMFA results.
    Opera TI; Waller CL; Marshall GR
    Drug Des Discov; 1994 Jul; 12(1):29-51. PubMed ID: 7578806
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Computational design of novel fullerene analogues as potential HIV-1 PR inhibitors: Analysis of the binding interactions between fullerene inhibitors and HIV-1 PR residues using 3D QSAR, molecular docking and molecular dynamics simulations.
    Durdagi S; Mavromoustakos T; Chronakis N; Papadopoulos MG
    Bioorg Med Chem; 2008 Dec; 16(23):9957-74. PubMed ID: 18996019
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 3D-QSAR CoMFA/CoMSIA models based on theoretical active conformers of HOE/BAY-793 analogs derived from HIV-1 protease inhibitor complexes.
    da Cunha EF; Sippl W; de Castro Ramalho T; Ceva Antunes OA; de Alencastro RB; Albuquerque MG
    Eur J Med Chem; 2009 Nov; 44(11):4344-52. PubMed ID: 19616874
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Three-dimensional quantitative structure-activity relationship study on cyclic urea derivatives as HIV-1 protease inhibitors: application of comparative molecular field analysis.
    Debnath AK
    J Med Chem; 1999 Jan; 42(2):249-59. PubMed ID: 9925730
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mapping the binding site of a large set of quinazoline type EGF-R inhibitors using molecular field analyses and molecular docking studies.
    Hou T; Zhu L; Chen L; Xu X
    J Chem Inf Comput Sci; 2003; 43(1):273-87. PubMed ID: 12546563
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative binding energy analysis of HIV-1 protease inhibitors: incorporation of solvent effects and validation as a powerful tool in receptor-based drug design.
    Pérez C; Pastor M; Ortiz AR; Gago F
    J Med Chem; 1998 Mar; 41(6):836-52. PubMed ID: 9526559
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 3D QSAR CoMFA/CoMSIA, molecular docking and molecular dynamics studies of fullerene-based HIV-1 PR inhibitors.
    Durdagi S; Mavromoustakos T; Papadopoulos MG
    Bioorg Med Chem Lett; 2008 Dec; 18(23):6283-9. PubMed ID: 18951793
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Binding interaction analysis of the active site and its inhibitors for neuraminidase (N1 subtype) of human influenza virus by the integration of molecular docking, FMO calculation and 3D-QSAR CoMFA modeling.
    Zhang Q; Yang J; Liang K; Feng L; Li S; Wan J; Xu X; Yang G; Liu D; Yang S
    J Chem Inf Model; 2008 Sep; 48(9):1802-12. PubMed ID: 18707092
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Insight into the structural requirements of urokinase-type plasminogen activator inhibitors based on 3D QSAR CoMFA/CoMSIA models.
    Bhongade BA; Gadad AK
    J Med Chem; 2006 Jan; 49(2):475-89. PubMed ID: 16420035
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Quantitative structure-activity relationship of human neutrophil collagenase (MMP-8) inhibitors using comparative molecular field analysis and X-ray structure analysis.
    Matter H; Schwab W; Barbier D; Billen G; Haase B; Neises B; Schudok M; Thorwart W; Schreuder H; Brachvogel V; Lönze P; Weithmann KU
    J Med Chem; 1999 Jun; 42(11):1908-20. PubMed ID: 10354399
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative molecular field analysis of flavonoid inhibitors of the PIM-1 kinase.
    Holder S; Lilly M; Brown ML
    Bioorg Med Chem; 2007 Oct; 15(19):6463-73. PubMed ID: 17637507
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Exploring binding mode for styrylquinoline HIV-1 integrase inhibitors using comparative molecular field analysis and docking studies.
    Ma XH; Zhang XY; Tan JJ; Chen WZ; Wang CX
    Acta Pharmacol Sin; 2004 Jul; 25(7):950-8. PubMed ID: 15210071
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Three-dimensional quantitative structure: activity relationship studies on diverse structural classes of HIV-1 integrase inhibitors using CoMFA and CoMSIA.
    Nunthaboot N; Tonmunphean S; Parasuk V; Wolschann P; Kokpol S
    Eur J Med Chem; 2006 Dec; 41(12):1359-72. PubMed ID: 17002889
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 3D-QSAR studies on malonyl coenzyme A decarboxylase inhibitors.
    Patel MR; Talele TT
    Bioorg Med Chem; 2007 Jul; 15(13):4470-81. PubMed ID: 17482825
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CoMFA 3D-QSAR analysis of HIV-1 RT nonnucleoside inhibitors, TIBO derivatives based on docking conformation and alignment.
    Zhou Z; Madura JD
    J Chem Inf Comput Sci; 2004; 44(6):2167-78. PubMed ID: 15554687
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Exploration of a binding mode of indole amide analogues as potent histone deacetylase inhibitors and 3D-QSAR analyses.
    Guo Y; Xiao J; Guo Z; Chu F; Cheng Y; Wu S
    Bioorg Med Chem; 2005 Sep; 13(18):5424-34. PubMed ID: 15963726
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 3D-QSAR CoMFA studies on bis-coumarine analogues as urease inhibitors: a strategic design in anti-urease agents.
    Zaheer-ul-Haq ; Lodhi MA; Ahmad Nawaz S; Iqbal S; Mohammed Khan K; Rode BM; Atta-ur-Rahman ; Choudhary MI
    Bioorg Med Chem; 2008 Mar; 16(6):3456-61. PubMed ID: 18280742
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CoMFA-based prediction of agonist affinities at recombinant D1 vs D2 dopamine receptors.
    Wilcox RE; Tseng T; Brusniak MY; Ginsburg B; Pearlman RS; Teeter M; DuRand C; Starr S; Neve KA
    J Med Chem; 1998 Oct; 41(22):4385-99. PubMed ID: 9784114
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 3D QSAR studies of AChE inhibitors based on molecular docking scores and CoMFA.
    Akula N; Lecanu L; Greeson J; Papadopoulos V
    Bioorg Med Chem Lett; 2006 Dec; 16(24):6277-80. PubMed ID: 17049234
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 3D-QSAR studies on chromone derivatives as HIV-1 protease inhibitors: application of molecular field analysis.
    Nunthanavanit P; Anthony NG; Johnston BF; Mackay SP; Ungwitayatorn J
    Arch Pharm (Weinheim); 2008 Jun; 341(6):357-64. PubMed ID: 18442018
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.